Significant role for Fas in the pathogenesis of autoimmune diabetes

Journal of Immunology

Volumn 164, Issue 5, 2000, Pages 2523-2532

  Su, Xiao ^a   Hu, Qile ^a   Kristan, Jane M ^a   Costa, Cristina ^a   Shen, Yamin ^a   Gero, Demokos ^a   Matis, Louis A ^a   Wang, Yi ^a  

^a ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; LIGAND;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; APOPTOSIS; ARTICLE; AUTOIMMUNITY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DIABETOGENESIS; GENE MUTATION; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE;

EID: 0034162513     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.5.2523     Document Type: Article

References (69)

1. Tisch, R., and H. McDevitt. 1996. Insulin-dependent diabetes mellitus. Cell 85: 291.
2. Wicker, L. S., J A. Todd,. and L. B. Peterson. 1995. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol. 13:179.
3. Bowman, M. A., E. H. Leiter, and M. A. Atkinson. 1994. Prevention of diabetes in the NOD mouse: implication for therapeutic intervention in human disease. Immunol. Today 15:115.
4. O'Brien, B. A., B. V. Harmon, D. P. Cameron, and D. J. Allan. 1997. Apoptosis is the mode of β-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes 46:750.
5. Stassi, G., R. D. Maria, G. Trucco, W. Rudert, R. Testi, A. Galluzzo, C. Giordano, and M. Trucco. 1997. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J. Exp. Med. 186:1193.
6. Chervonsky, A. V., Y. Wang, F. S. Wong, I. Visintin, R. A. Flavell, C. A. Janeway, Jr., and L. A. Matis. 1997. The role of Fas in autoimmune diabetes. Cell 89:17.
7. Itoh, N., A. Imagawa, T. Hanafusa, M. Waguri, K. Yamamoto, H. Iwahashi, M. Moriwaki, H. Nakajima, J. Miyagawa, M. Namba, et al. 1997. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186:613.
8. Kagi, D., B. Odermatt, P. Seiler, R. M. Zinkernagel, T. W. Mak, and H. Hengartner. 1997. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J. Exp. Med. 186:989.
9. Yang, X., R. Tisch, S. M. Singer, Z. A. Cao, R. S. Liblau, R. D. Schreiber, and H. O. McDevitt. 1994. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J. Exp. Med. 180:995.
10. Kagi, D., A. Ho, B. Odermatt, A. Zakarian, P. S. Ohashi, and T. W. Mak. 1999. TNF receptor 1-dependent β cell toxicity as an effector pathway in autoimmune diabetes. J. Immunol. 162:4598.
11. Pakala, S. V., M. Chivetta, C. B. Kelly, and J. D. Katz. 1999. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor α. J. Exp. Med. 189:1053.
12. Green, E. A., E. E. Eynon, and R. A. Flavell. 1998. Local expression of TNF or in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 9:733.
13. Grewal, I. S., K. D. Grewal, F. S. Wong, D. E. Picarella, C. A. Janeway, Jr., and R. A. Flavell. 1996. Local expression of transgene encoded TNF or in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J. Exp. Med. 184:1963.
14. Suarez-Pinzon, W., O. Sorensen, R. C. Bleackley, J. F. Elliott, R. V. Rajotte, and A. Rabinovitch. 1999. β-Cell destruction in NOD mice correlates with Fas (CD95) expression on β-cells and proinflammatory cytokine expression in islets. Diabetes 48:21.
15. Watanabe-Fukunaga R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.
16. Chu, J. L., P. Ramos, A. Rosendorff, J. Nikolic-Zugic, E. Lacy, A. Matsuzawa, and K. B. Elkon. 1995. Massive upregulation of the Fas ligand in lpr and gld mice: implication for Fas regulation and the graft-versus-host disease-like wasting syndrome. J. Exp. Med. 181:393.
17. Allison, J., and A. Strasser. 1998. Mechanisms of β cell diabetes: a minor role for CD95. Proc. Natl. Acad Sci. USA 95:13818.
18. Ikegami, H., S. Makino, E. Yamato, Y. Kawaguchi, H. Ueda, T. Sakamoto, K. Takekawa, and T. Ogihara. 1995. Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. J. Clin. Invest. 96:1936.
19. Araki, R., A. Fujimori, K. Hamatani, K. Mita, T. Saito, M. Mon, R. Fukumura, M. Morimyo, M. Muto, M. Itoh, et al. 1997. Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice. Proc. Natl. Acad. Sci. USA 94:2438.
20. Wicker, L. S., B. J. Miller, and Y. Mullen. 1986. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 35:855.
21. Kayagaki, N., N. Yamaguchi, F. Nagao, S. Matsuo, H. Maeda, K. Okumura, and H. Yagita. 1997. Polymorphism of murine Fas ligand that affects the biological activity Proc. Natl. Acad. Sci. USA 94:3914.
22. Vyse, T. J., and J. A. Todd. 1996. Genetic analysis of autoimmune disease. Cell 85:311.
23. Watanabe-Fukunaga, R., C. I. Brannan, N. Itoh, S. Yonehara, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148:1274.
24. Lynch, D. H., M. L. Watson, M. R. Alderson, P. R. Baum, R. E. Miller, T. Tough, M. Gibson, T. Davis-Smith, C. A. Smith, and K. Hunter. 1994. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1:131.
25. Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969.
26. Reap, E. A., K. Roof, K. Maynor, M. Borrero, J. Booker, and P. L. Cohen. 1997. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc. Natl. Acad. Sci. USA 94:5750.
27. Cohen, J. J., R. C. Duke, V. A. Fadok, and K. S. Sellins. 1992. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 10:267.
28. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
29. Fisher, G. H., F. J. Rosenberg, S. E. Straus, J. K. Dale, L. A. Middleton, A. Y. Lin, W. Strober, M. J. Lenardo, and J. M. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935.
30. Drappa, J., A. K. Vaishnaw, K. E. Sullivan, J. L. Chu, and K. B. Elkon. 1996. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med 335:1643.
31. Bettinardi, A., D. Brugnoni, E. Quiros-Roldan, A. Malagoli, S. La Grutta, A. Correra, and L. D. Notarangelo. 1997. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immu-nological analysis. Blood 89:902.
32. Wu, J., J. Wilson, J. He, L. Xiang, P. H. Schur, and J. D. Mountz. 1996. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J. Clin. Invest. 98:1107.
33. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.
34. Takeda, Y., M. Gotoh, K. Dono, M. Nishihara, T. Grochowiecki, F. Kimura, T. Yoshida, Y. Ohta, H. Ota, H. Ohzato, et al. 1998. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts Diabetologia 41:315.
35. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189.
36. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
37. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
38. Nagata, S. 1996. Fas ligand and immune evasion. Nat. Med. 2:1306.
39. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, D. Roche, J. Kelly, J. K. Collins, and F. Shanahan. 1998. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 186:240.
40. Sabelko, K. A., K. A. Kelly, M. H. Nahm, A. H. Cross, and J. H. Russell. 1997. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:3096.
41. Waldner, H., R. A. Sobel, E. Howard, and V. K. Kuchroo. 1997. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159:3100.
42. Okuda, Y., C. C. Bernard, H. Fujimura, T. Yanagihara, and S. Sakoda. 1998. Fas has a crucial role in the progression of experimental autoimmune encephalomyelitis. Mol. Immunol. 35:317.
43. Sabelko-Downes, K. A., A. H. Cross, and J. H. Russell. 1999. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med. 189:1195.
44. Giordano, C., G. Stassi, R. De Maria, M. Todaro, P. Richiusa, G. Papoff, G. Ruberti, M. Bagnasco, R. Testi, and A. Galluzzo. 1997. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275:960.
45. Ishiyama, S., M. Hiroe, T. Nishikawa, T. Shimojo, S. Abe, H. Fujisaki, H. Ito, K. Yamakawa, N. Kobayashi, T. Kasajima, et al. 1998. The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats. J. Immunol. 161:4695.
46. Kendo, T., T. Suda, H. Fukuyama, M. Adachi, and S. Nagata. 1997. Essential role of Fas ligand in the development of hepatitis. Nat. Med. 3:409.
47. Galle, P. R., W. J. Hofmann, H. Walczak, H. Schaller, G. Otto, W. Stremmel, P. H. Krammer, and L. Runkel. 1995. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1223.
48. Rudi, J., D. Kuck, S. Strand, A. von Herbay, S. M. Mariani, P. H. Krammer, P. R. Galle, and W. Stremmel. 1998. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J. Clin. Invest. 102:1506.
49. Takahashi, T., M. Tanaka, J. Inazawa, T. Abe, T. Suda, and S. Nagata. 1994. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 6:1567.
50. Yamada, K., N. Takane-Gyotoku, X. Yuan, F. Ichikawa, C. Inada, and K. Nonaka. 1996. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 39:1306.
51. Stassi, G., M. Todaro, P. Richiusa, M. Giordano, A. Mattina, M.S. Sbriglia, A. Lo Monte, G. Buscemi, A. Galluzo, and C. Giordano. 1995. Expression of apoptosis-inducing CD95 (Fas/Apo-1) of human β-cells sorted by flow cytometry and cultured in vitro. Transplant. Proc. 27:3271.
52. Mandrup-Poulsen, T., K. Bendtzen, C.A., Dinarello, and J. Nerup. 1987. Human necrosis factor potentiates human interlukin-1 mediated rat pancreatic β-cell cytotoxicity. J. Immunol. 139:4077.
53. Cetkovic-Cvrlje, M., and D. L. Eizirik. 1994. TNF-α and IFN-γ potentiate the deleterious effects of IL-1β on mouse pancreatic islets mainly via generation of nitric oxide. Cytokines 6:399.
54. Heitmeier, M. R., A. L. Scarim, and J. A. Corbett. 1997. IFN-γ increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J. Biol. Chem. 272:13697.
55. + T lymphocytes in transgenic nonobese diabetic mice. J. Clin. Invest. 103:1201.
56. Rabinovitch, A., and W. L. Suarez-Pinzon. 1998. Cytokines and their roles in pancreatic islet β cell destruction and insulin-dependent diabetes mellitus. Biochem. Pharmacol. 55:1139.
57. Bendtzen, K., T. Mandrup-Poulsen, J. Nerup, J. H. Nielsen, C. A. Dinarello, and M. Svenson. 1986. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232:1545.
58. Campbell, I. L., A. Iscaro, and L. C. Harrison. 1988. INF-γ and tumor necrosis factor-α cytotoxicity to murine islets of Langerhans. J. Immunol. 141:2325.
59. Hunger, R. E., C. Carnaud, I. Garcia, P. Vassalli, and C. Mueller. 1997. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor p55. Eur. J. Immunol. 27:255.
60. Sarvetnick, N., D. Liggitt, S. L. Pitts, S. E. Hansen, and T. A. Stewart. 1988. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-γ. Cell 52:773.
61. von Herrath, M. G., and M. B. A. Oldstone. 1996. Interferon γ is essential for destruction of β cells and development of insulin-dependent diabetes mellitus. J. Exp. Med. 185:531.
62. Wang, B., I, Andre, A. Gonalez, J. D. Katz, M. Aguet, C. Benoist, and D. Mathis. 1997. Interferon-γ impacts at multiple points during the progression of autoimmune diabetes. Proc. Natl. Acad. Sci. USA 94:13844.
63. Nomikos, I. N., S. J. Prowse, P. Carotenuto, and K. J. Lafferty. 1986. Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 35:1302.
64. 2 radicals in autoimmune diabetes. Immunol. Cell. Biol. 67:85.
65. Sumoski, W., H. Baquerizo, and A. Rabinovitch. 1989. Oxygen free radical scavengers protect rat islet cells from damage by cytokines. Diabetologia 32:792.
66. Yoon, J. W., H. S. Jun, and P. Santamaria. 1998. Cellular and molecular mechanisms for the initiation and progression of β cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 27:109.
67. Benoist, C., and D. Mathis. 1997. Cell death mediators in autoimmune diabetes: no shortage of suspects. Cell 89:1.
68. Elliott, E. A., H. I. McFarland, S. H. Nye, R. Cofiell, T. M. Wilson, J. A. Wilkins, S. P. Squinto, L. A. Matis, and J. P. Mueller. 1996. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest. 98:1602.
69. Zhou, T., L. Song, P. Yang, Z. Wang, D. Lui, and R. S. Jope. 1999. Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat. Med. 5:42.